Exploring bias in platelet P2Y 1 signalling: Host defence versus haemostasis
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16191 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Dingxin Pan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, UK. Hauptthemen laut MEDLINE: Blood Platelets, Platelet Aggregation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Platelets are necessary for maintaining haemostasis. Separately, platelets are important for the propagation of inflammation during the host immune response against infection. The activation of platelets also causes inappropriate inflammation in various disease pathologies, often in the absence of changes to haemostasis. The separate functions of platelets during inflammation compared with haemostasis are therefore varied and this will be reflected in distinct pathways of activation. The activation of platelets by the nucleotide adenosine diphosphate (ADP) acting on P2Y 1 and P2Y 12 receptors is important for the development of platelet thrombi during haemostasis. However, P2Y 1 stimulation of platelets is also important during the inflammatory response and paradoxically in scenarios where no changes to haemostasis and platelet aggregation occur. In these events, Rho‐GTPase signalling, rather than the canonical phospholipase Cβ (PLCβ) signalling pathway, is necessary. We describe our current understanding of these differences, reflecting on recent advances in knowledge of P2Y 1 structure, and the possibility of biased agonism occurring from activation via other endogenous nucleotides compared with ADP. Knowledge arising from these different pathways of P2Y 1 stimulation of platelets during inflammation compared with haemostasis may help therapeutic control of platelet function during inflammation or infection, while preserving essential haemostasis. LINKED ARTICLES This article is part of a themed issue on Platelet purinergic receptor and non‐thrombotic disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.4/issuetoc
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, UK.
- Department of Pharmacology, University of Cambridge, Cambridge, UK.
- Chemical Biology Group, Institute of Pharmaceutical Science, King's College London, London, UK.
ORCID-Profile: Khondaker Miraz Rahman, Simon C Pitchford
Förderung
- Medical Research Council
Zitieren
APA
Pan, D., Ladds, G., Rahman, K. M., & Pitchford, S. C. (2024). Exploring bias in platelet P2Y 1 signalling: Host defence versus haemostasis. British Journal of Pharmacology. https://doi.org/10.1111/bph.16191
Vancouver
Pan D, Ladds G, Rahman KM, Pitchford SC. Exploring bias in platelet P2Y 1 signalling: Host defence versus haemostasis. British Journal of Pharmacology. 2024. doi:10.1111/bph.16191
BibTeX
@article{Pan2024,
author = {Pan, Dingxin and Ladds, Graham and Rahman, Khondaker Miraz and Pitchford, Simon C},
title = {Exploring bias in platelet P2Y 1 signalling: Host defence versus haemostasis},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16191}
}
EUVIMED